MCL-1 inhibitor antibody-drug conjugates and methods of use

JP2023553808A5Inactive Publication Date: 2024-11-28NOVARTIS AG +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2023530996
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2020-11-24
Filing Date
2021-11-23
Publication Date
2024-11-28
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 2022115451000001
    Figure 2022115451000001
  • Figure 2022115451000002
    Figure 2022115451000002
  • Figure 2022115451000003
    Figure 2022115451000003
Patent Text Reader

Abstract

Anti-CD48 antibody-drug conjugates are disclosed. The anti-CD48 antibody-drug conjugates comprise an Mcl-1 inhibitor drug moiety and an anti-CD48 antibody or antigen-binding fragment thereof that binds an antigen target, e.g., an antigen expressed on tumor or other cancer cells. The present disclosure further relates to methods and compositions for use in treating cancer by administering the antibody-drug conjugates provided herein. Linker-drug conjugates comprising an Mcl-1 inhibitor drug moiety and methods for preparing the same are also disclosed.
Need to check novelty before this filing date? Find Prior Art

Claims

1. Formula (1): Ab-(L-D) p (1) [In the formula, Ab is an anti-CD48 antibody or an antigen-binding fragment thereof; p is an integer from 1 to 16; -(L-D) is a compound of the formula (C): [Formula 1] (In the formula, R 1 is a linking group, L 1 is a bridging spacer, L p is a peptide group containing 1 to 6 amino acids, D is an Mcl-1 inhibitor; G 1 -L 2 -A is a self-immolative spacer, L 2 is a bond, methylene, neopentylene or C 2 ~C 3 alkenylene, A is a bond, -OC(=O)- * , [chemical 2] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, L 3 is a spacer moiety, R 2 is the hydrophilic portion) [The following is a list of An antibody-drug conjugate of the formula: The anti-CD48 antibody or antigen-binding fragment is an antibody-drug conjugate comprising three heavy chain CDRs and three light chain CDRs as follows: (i) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 1, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 2, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 3; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 16, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 17, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (ii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 4, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 2, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 3; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 16, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 17, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (iii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO:5, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO:6, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO:3; a light chain CDR1 (LCDR1) consisting of SEQ ID NO:19, a light chain CDR2 (LCDR2) consisting of SEQ ID NO:20, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO:21; (iv) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 7, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 8, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 9; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 22, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 20, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 18; (v) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO:27, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO:28, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO:29; a light chain CDR1 (LCDR1) consisting of SEQ ID NO:42, a light chain CDR2 (LCDR2) consisting of SEQ ID NO:43, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO:44; (vi) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 30, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 28, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 29; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 42, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 43, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 44; (vii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 31, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 32, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 29; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 45, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 46, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO: 47; or (viii) a heavy chain CDR1 (HCDR1) consisting of SEQ ID NO: 33, a heavy chain CDR2 (HCDR2) consisting of SEQ ID NO: 34, a heavy chain CDR3 (HCDR3) consisting of SEQ ID NO: 35; a light chain CDR1 (LCDR1) consisting of SEQ ID NO: 48, a light chain CDR2 (LCDR2) consisting of SEQ ID NO: 46, and a light chain CDR3 (LCDR3) consisting of SEQ ID NO:

44.

2. -(LD) is a compound of the formula (D): [C3] (In the formula, R 1 is a linking group, L 1 is a bridging spacer, Lp is a peptide group containing 1 to 6 amino acids; A is a bond, -OC(=O)- * , [C4] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, L 3 is a spacer moiety, R 2 is the hydrophilic portion) 2. The antibody-drug conjugate of claim 1, or a pharma- ceutically acceptable salt thereof.

3. (i) L 1 but, [C5] or * -CH(OH)CH(OH)CH(OH)CH(OH)- ** Including, where each n is an integer from 1 to 12, where L 1 of * indicates a direct or indirect attachment point to Lp, and L 1 of ** is R 1 indicates the point of direct or indirect attachment to; (ii) L 1 is [C6] wherein n is an integer from 1 to 12, or n is 1, or n is 12, and wherein * of L 1 indicates the point of direct or indirect attachment to Lp, and ** of L 1 indicates the point of direct or indirect attachment to R 1 ; (iii) L 1 is [C7] and n is an integer from 1 to 12, in which the * of L 1 indicates the point of direct or indirect attachment to Lp, and the ** of L 1 indicates the point of direct or indirect attachment to R 1 ; (iv) L 1 is [C8] wherein * of L 1 indicates the point of direct or indirect attachment to Lp, and ** of L 1 indicates the point of direct or indirect attachment to R 1 ; or (v) L 1 is * -C(=O)(CH 2 ) m O(CH 2 ) m - ** ; * -C(=O)((CH 2 ) m O) t (CH 2 ) n - ** ; * -C(=O)(CH 2 ) m - **; * -C(=O)NH((CH 2) m O) t (CH 2 ) n - ** ; * -C(=O)O(CH 2 ) m SSC(R 3 ) 2 (CH 2 ) m C(=O)NR 3 (CH 2 ) m NR 3 C(=O) (CH 2 ) m - ** ; * -C(=O)O(CH 2 ) m C(=O)NH(CH 2 ) m - ** * -C(=O)(CH 2 ) m NH(CH 2 ) m - ** ; * -C(=O)(CH 2 ) m NH(CH 2 ) n C(=O)- ** ; * -C(=O)(CH 2 ) m X 1 (CH 2 ) m - ** * -C(=O)((CH 2 ) m O) t (CH 2 ) n X 1 (CH 2 ) n - ** ; * -C(=O)(CH 2 ) m NHC(=O)(CH 2 ) n - **; O) t (CH 2 ) n NHC(=O)(CH 2 ) n - ** ; * -C(=O)(CH 2 ) m NHC(=O)(CH 2 ) n ) n - ** ; * -C(=O)((CH 2 ) m O) t (CH 2 ) n C(=O)NH(CH 2 ) m - ** ; * -C(=O)(CH 2 ) m C(R 3 ) 2 - ** or * -C(=O) (CH 2 ) m C(=O)NH(CH 2 ) m - ** wherein * of L 1 indicates a direct or indirect point of attachment to Lp, and ** of L 1 indicates a direct or indirect point of attachment to R 1 ; X 1 is [C9] and each m is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; each n is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, and 10; each t is independently selected from 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, and 30; The antibody-drug conjugate of claim 1 or 2, wherein each R 3 is independently selected from H and C 1 -C 6 alkyl.

4. (1) R 2 Polyethylene glycol, polyalkylene glycol, polyol, polysarcosine, sugar, oligosaccharide, polypeptide, 1 to 3 [C10] C substituted with a group 2 ~C 6 Alkyl, or -OC(=O)NHS(O) 2 N.H.C.H. 2 CH 2 OCH 3 , -NHC(=O)C 1~4 Alkylene-P(O)(OCH 2 CH 3 ) 2 and C substituted with 1 or 2 substituents independently selected from -COOH groups. 2 ~C 6 is an alkyl-containing hydrophilic moiety; (2) R 2 is [C11] where n is an integer between 1 and 6. [C12] is; (3) The hydrophilic portion is (i) the part: [C13] where n is an integer between 3 and 25 and R is H, -CH3 or -CH2CH2C(=O)OH; or (ii) Formula: [C14] Polyethylene glycol: A moiety represented by the formula: wherein R is H, -CH 3 , -CH 2 CH 2 NHC(=O)OR a , -CH 2 CH 2 NHC(=O)R a or -CH 2 CH 2 C(=O)OR a ; R' is OH, -OCH 3 , -CH 2 CH 2 NHC(=O)OR a , -CH 2 CH 2 NHC(=O)R a or -OCH 2 CH 2 C(=O)OR a ; where R a is H or C 1-4 alkyl optionally substituted with either OH or C 1-4 alkoxyl; and each of m and n is independently an integer between 2 and 25. or (4) The hydrophilic portion is [C15] The antibody-drug conjugate of any one of claims 1 to 3, comprising:

5. (i) L 3 But the structure [C16] (In the formula, W is -CH 2 --, --CH 2 O-, -CH 2 N (R b )C(=O)O-, -NHC(=O)C(R b ) 2 NHC(=O)O-, -NHC(=O)C(R b ) 2 NH-, -NHC(=O)C(R b ) 2 NHC(=O)-,-CH 2 N (X-R 2 )C(=O)O-, -C(=O)N(X-R 2 ) -, -CH 2N (X-R 2 )C(=O)-, -C(=O)NR b -, -C(=O)NH-, -CH 2 N.R. b C(=O)-, -CH 2 N.R. b C(=O)NH-, -CH 2 N.R. b C(=O)NR b -, -NHC(=O)-, -NHC(=O)O-, -NHC(=O)NH-, -OC(=O)NH-, -S(O) 2 NH-, -NHS(O) 2 -, -C(=O)-, -C(=O)O-, or -NH-, where each R b is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; X is a bond, triazolyl or -CH 2 -triazolyl-, where X is R 2 connected to or (ii) L 3 But the structure [C17] (In the formula, W is -CH 2 --, --CH 2 O-, -CH 2 N (R b )C(=O)O-, -NHC(=O)C(R b ) 2 NHC(=O)O-, -NHC(=O)C(R b ) 2 NH-, -NHC(=O)C(R b ) 2 NHC(=O)-,-CH 2 N (X-R 2 )C(=O)O-, -C(=O)N(X-R 2 ) -, -CH 2 N (X-R 2 )C(=O)-, -C(=O)NR b-, -C(=O)NH-, -CH 2 N.R. b C(=O)-, -CH 2 N.R. b C(=O)NH-, -CH 2 N.R. b C(=O)NR b -, -NHC(=O)-, -NHC(=O)O-, -NHC(=O)NH-, -OC(=O)NH-, -S(O) 2 NH-, -NHS(O) 2 -, -C(=O)-, -C(=O)O-, or -NH-, where each R b is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; X is -CH 2 -Triazolyl-C 1~4 Alkylene-OC(O)NHS(O) 2 NH-, -C 4~6 Cycloalkylene-OC(O)NHS(O) 2 NH-, -(CH 2 CH 2 O) n -C(O)NHS(O) 2 NH-, -(CH 2 CH 2 O) n -C(O)NHS(O) 2 NH-(CH 2 CH 2 O) n - or -CH 2 -Triazolyl-C 1~4 Alkylene-OC(O)NHS(O) 2 NH-(CH 2 CH 2 O) n -, where each n is independently 1, 2, or 3, and where X is R 2 connected to The antibody-drug conjugate according to any one of claims 1 to 4, wherein the spacer moiety has the formula: (i) the linking group is formed by a reaction involving at least one reactive group; (ii) the linking group is a first reactive group attached to the linker; formed by reacting with a second reactive group that is attached to the antibody or is an amino acid residue of the antibody; (iii) at least one of the reactive groups is Thiol, Maleimide, Haloacetamides, Azide, Alkynes, Cyclooctene, Triarylphosphines, oxanorbornadiene, Cyclooctyne, Diaryltetrazines, Monoaryltetrazines, Norbornene, aldehyde, Hydroxylamine, Hydrazine, NH 2 -NH-C(=O)-, Ketones, vinyl sulfone, Aziridine, Amino acid residues, [C18] , -ONH 2 , -NH 2 , [C19] , -N3, [C20] , -SH, -SR 3 , -SSR 4 , -S(=O) 2 (CH=CH 2 ), -(CH 2 ) 2 S(=O) 2 (CH=CH 2 ), -NHS(=O) 2 (CH=CH 2 ), -NHC(=O)CH 2 Br, -NHC(=O)CH 2 I, [C21] , -C(O)NHNH 2 , [C22] Including, Where: each R 3 is independently selected from H and C 1 -C 6 alkyl; each R 4 is 2-pyridyl or 4-pyridyl; each R 5 is independently selected from H, C 1 -C 6 alkyl, F, Cl, and —OH; each R 6 is independently selected from H, C 1 -C 6 alkyl, F, Cl, —NH 2 , —OCH 3 , —OCH 2 CH 3 , —N(CH 3 ) 2 , —CN, —NO 2 , and —OH; each R 7 is independently selected from H, C 1-6 alkyl, fluoro, benzyloxy substituted with -C(=O)OH, benzyl substituted with -C(=O)OH, C 1-4 alkoxy substituted with -C(=O)OH, and C 1-4 alkyl substituted with -C(=O)OH; (iv) the first reactive group and the second reactive group are Thiols and maleimides, Thiols and haloacetamides, Thiols and vinyl sulfones, Thiols and aziridines, Azides and alkynes, Azide and cyclooctyne, Azide and cyclooctene, Azides and triarylphosphines, Azides and oxanorbornadienes, diaryltetrazines and cyclooctenes, Monoaryltetrazines and norbornenes, Aldehydes and hydroxylamines, Aldehydes and hydrazines, Aldehydes and NH 2 —NH—C(═O)—, Ketones and hydroxylamines, Ketones and hydrazines, Ketones and NH 2 —NH—C(═O)—, Hydroxylamine and [C23] , Amines and [C24] ,or CoA or CoA analog and serine residue or (v) the linking group is [Case 25-1] [Case 25-2] [Case 25-3] amide; [C26] and Disulfides and Where: R 32 is H, C 1-4 alkyl, phenyl, pyrimidine or pyridine; R 35 is H, C 1-6 alkyl, phenyl, or C 1-4 alkyl substituted with 1 to 3 -OH groups; each R 7 is independently selected from H, C 1-6 alkyl, fluoro, benzyloxy substituted with —C(═O)OH, benzyl substituted with —C(═O)OH, C 1-4 alkoxy substituted with —C(═O)OH, and C 1-4 alkyl substituted with —C(═O)OH; R 37 is independently selected from H, phenyl and pyridine; q is 0, 1, 2 or 3; R 8 is H or methyl; The antibody-drug conjugate of any one of claims 1 to 5, wherein R 9 is H, -CH 3 or phenyl.

7. (i) the peptide group contains 1 to 4 amino acid residues, 1 to 3 amino acid residues, or 1 or 2 amino acid residues; (ii) said amino acid residues are selected from L-glycine (Gly), L-valine (Val), L-citrulline (Cit), L-cysteic acid (sulfo-Ala), L-lysine (Lys), L-isoleucine (Ile), L-phenylalanine (Phe), L-methionine (Met), L-asparagine (Asn), L-proline (Pro), L-alanine (Ala), L-leucine (Leu), L-tryptophan (Trp) and L-tyrosine (Tyr); (iii) the peptide group comprises Val-Cit, Phe-Lys, Val-Ala, Val-Lys, Leu-Cit, Sulfo-Ala-Val and / or Sulfo-Ala-Val-Ala; or (iv) Lp is [C27] The antibody-drug conjugate according to any one of claims 1 to 6, wherein the antibody-drug conjugate is selected from the group consisting of

8. -(L-D) is a compound of the formula: (1) [C28] (In the formula, R is H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [C29] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (2) [C30] (In the formula, R is H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [C31] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (3) [C32] (In the formula, R is H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [C33] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (4) [C34] (In the formula, Each R is H, —CH 3 and -CH 2 CH 2 C(═O)OH; A is a bond, -OC(=O)- * , [C35] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (5) [C36] (In the formula, Each R is H, —CH 3 and -CH 2 CH 2 C(═O)OH; A is a bond, -OC(=O)- * , [C37] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (6) [C38] (In the formula, Xa is -CH 2 --, --OCH 2 --NHCH 2 -or- NRCH 2 -, and each R is independently H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [C39] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (7) [C40] (In the formula, R is H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [C41] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (8) [C42] (In the formula, Xb is -CH 2 --, --OCH 2 --NHCH 2 -or- NRCH 2 -, and each R is independently H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [C43] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (9) [C44] (In the formula, A is a bond, -OC(=O)- * , [C45] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (10) [C46] (In the formula, A is a bond, -OC(=O)- * , [C47] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (11) [C48] (In the formula, A is a bond, -OC(=O)- * , [C49] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (12) [50] (In the formula, A is a bond, -OC(=O)- * , [C51] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; *indicates the point of attachment to D, D is an Mcl-1 inhibitor. (13) [C52] (In the formula, A is a bond, -OC(=O)- * , [C53] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (14) [C54] (In the formula, A is a bond, -OC(=O)- * , [C55] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor. (15) [C56] (In the formula, A is a bond, -OC(=O)- * , [C57] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor, or (16) [C58] (In the formula, Each R is independently H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [C59] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor, or (17) [60] (In the formula, Each R is independently H, -CH 3 or -CH 2 CH 2 C(=O)OH, A is a bond, -OC(=O)- * , [61] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, n is an integer between 2 and 24; D is an Mcl-1 inhibitor, or (18) [62] (In the formula, A is a bond, -OC(=O)- * , [63] , -OC(=O)N(CH 3 ) CH 2 CH 2 N (CH 3 ) C(=O)- * Or -OC(=O)N(CH 3 ) C(R a ) 2 C(R a ) 2 N (CH 3 ) C(=O)- * and Here, each R a is H, C 1 ~C 6 Alkyl and C 3 ~C 8 cycloalkyl; * indicates the point of attachment to D, D is an Mcl-1 inhibitor.

8. The antibody-drug conjugate of claim 1 , comprising or formed from a compound of the formula:

9. A is a bond, The antibody-drug conjugate of any one of claims 1 to 8, wherein R is -CH 3 . (i) D is a compound of formula (I): [64] (In the formula, Ring D 0 is a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, Ring E 0 is a furyl, thienyl or pyrrolyl ring; X 01 , X 03, X 04 and X 05 are each independently a carbon atom or a nitrogen atom, X 02 is C-R 026 group or a nitrogen atom, [65] means that the ring is aromatic, Y 0 is a nitrogen atom or C-R 03 It is based on Z 0 is a nitrogen atom or C-R 04 It is based on R 01 is a halogen atom, a linear or branched (C 1 ~C 6 ) alkyl group, linear or branched (C 2 ~C 6 ) alkenyl group, linear or branched (C 2 ~C 6 ) alkynyl group, linear or branched (C 1 ~C 6 ) haloalkyl group, hydroxy group, hydroxy(C 1 ~C 6 ) alkyl group, linear or branched (C 1 ~C 6 ) alkoxy group, —S—(C 1 ~C 6 ) Alkyl group, cyano group, nitro group, -Cy 08 , -(C 0 ~C 6 ) alkyl-NR 011 R 011 ', -O-(C 1 ~C 6 ) alkyl-NR 011 R 011 ', -O-(C 1 ~C 6 ) alkyl-R 012 , —C(O)—OR 011 , -O-C(O)-R 011 , —C(O)—NR 011 R 011 ', -NR 011 -C(O)-R 011 ', -NR 011 -C(O)-OR 011 ', - (C 1 ~C 6 ) alkyl-NR 011 -C(O)-R 011 ',-SO 2 -NR 011 R 011 ' or -SO 2 - (C 1 ~C 6 ) alkyl; R 02 , R 03 , R 04 and R 05 are each independently a hydrogen atom, a halogen atom, a linear or branched (C 1 ~C 6 ) alkyl group, linear or branched (C 2 ~C 6 ) alkenyl group, linear or branched (C 2 ~C 6 ) alkynyl group, linear or branched (C 1 ~C 6 ) haloalkyl, hydroxy group, hydroxy (C 1 ~C 6 ) alkyl group, linear or branched (C 1 ~C 6 ) alkoxy group, —S—(C 1 ~C 6 ) alkyl group, cyano group, nitro group, -(C 0 ~C 6 ) alkyl-NR 011 R 011 ', -O-Cy 01 , -(C 0 ~C 6 ) Alkyl-Cy 01 , - (C 2 ~C 6 ) Alkenyl-Cy 01 , -(C 2 ~C 6 ) Alkynyl-Cy 01 , -O-(C 1 ~C 6 ) alkyl-NR 011 R 011 ', -O-(C 1 ~C 6 ) alkyl-R 031 , -O-(C 1 ~C 6 ) alkyl-R 012 , —C(O)—OR 011 , -O-C(O)-R 011 , —C(O)—NR 011 R 011 ', -NR 011 -C(O)-R 011 ', -NR 011 -C(O)-OR 011 ', - (C 1 ~C 6 ) alkyl-NR 011 -C(O)-R 011 ', -SO 2 -NR 011 R 011 ', or -SO 2 - (C 1 ~C 6 ) alkyl; Or against (R 01 , R 02 ), (R 02 , R 03 ), (R 03 , R 04 ) or (R 04 , R 05 ) together with the carbon atom to which they are attached form an aromatic or non-aromatic ring containing 5 to 7 ring members, optionally containing 1 to 3 heteroatoms selected from O, S and N, wherein the resulting ring is not further restricted by halogen, linear or branched (C 1 ~C 6 ) alkyl, (C 0 ~C 6 ) alkyl-NR 011 R 011 ', -NR 013 R 013 ', - (C 0 ~C 6 ) Alkyl-Cy 01 or oxo; R 06 and R 07are each independently a hydrogen atom, a halogen atom, a linear or branched (C 1 ~C 6 ) alkyl group, linear or branched (C 2 ~C 6 ) alkenyl group, linear or branched (C 2 ~C 6 ) alkynyl group, linear or branched (C 1 ~C 6 ) haloalkyl, hydroxyl, linear or branched (C 1 ~C 6 ) alkoxy group, —S—(C 1 ~C 6 ) alkyl group, cyano group, nitro group, -(C 0 ~C 6 ) alkyl-NR 011 R 011 ', -O-(C 1 ~C 6 ) alkyl-NR 011 R 011 ', -O-Cy 01 , -(C 0 ~C 6 ) Alkyl-Cy 01 , -(C 2 ~C 6 ) Alkenyl-Cy 01 , - (C 2 ~C 6 ) Alkynyl-Cy 01 , -O-(C 1 ~C 6 ) alkyl-R 012 , —C(O)—OR 011 , -O-C(O)-R 011 , -C(O)-NR 011 R 011 ', -NR 011 -C(O)-R 011 ', -NR 011 -C(O)-OR 011 ', - (C 1 ~C 6 ) alkyl-NR 011 -C(O)-R 011 ',-SO 2 -NR 011 R 011 ', or -SO 2 - (C 1 ~C 6 ) alkyl; Or against (R 06 , R 07 ), when fused with two adjacent carbon atoms, together with the carbon atoms to which they are attached, form an aromatic or non-aromatic ring containing 5 to 7 ring members, optionally containing 1 to 3 heteroatoms selected from O, S and N, wherein the resulting ring may be linear or branched (C 1 ~C 6 ) an alkyl group, —NR 013 R 013 ', - (C 0 ~C 6 ) Alkyl-Cy 01 or oxo, W 0 is -CH 2 - group, -NH- group or an oxygen atom, R 08 is a hydrogen atom, a linear or branched (C 1 ~C 8 ) an alkyl group, —CHR 0a R 0b group, aryl group, heteroaryl group, aryl (C 1 ~C 6 ) alkyl group or heteroaryl (C 1 ~C 6 ) alkyl group, R 09 is a hydrogen atom, a linear or branched (C 1 ~C 6 ) alkyl group, linear or branched (C 2 ~C 6 ) alkenyl group, linear or branched (C 2 ~C 6 ) an alkynyl group, -Cy 02 , -(C 1 ~C 6 ) Alkyl-Cy 02 , -(C 2 ~C 6 ) Alkenyl-Cy 02 , -(C 2 ~C 6 ) Alkynyl-Cy 02 , -Cy 02 -Cy 03 , -(C 2 ~C 6 ) Alkynyl-O-Cy 02 , -Cy 02 - (C 0 ~C 6 ) alkyl-O-(C 0 ~C 6 ) Alkyl-Cy 03 , a halogen atom, a cyano group, —C(O)—R 014 or -C(O)-NR 014 R 014 ' and R 010 is a hydrogen atom, a linear or branched (C 1 ~C 6 ) alkyl group, linear or branched (C 2 ~C 6 ) alkenyl group, linear or branched (C 2 ~C 6 ) alkynyl group, aryl (C 1 ~C 6 ) alkyl group, (C 1 ~C 6 ) cycloalkylalkyl group, linear or branched (C 1 ~C 6 ) haloalkyl or -(C 1 ~C 6 ) alkyl-O-Cy 04 and Or against (R 09 , R 010 ), when fused with two adjacent carbon atoms, together with the carbon atoms to which they are attached, form an aromatic or non-aromatic ring containing 5 to 7 ring members, optionally containing 1 to 3 heteroatoms selected from O, S and N; R 011 and R 011 ' are each independently a hydrogen atom, an optionally substituted linear or branched (C 1 ~C 6 ) alkyl group, or -(C 0 ~C 6 ) Alkyl-Cy 01 and Or against (R 011 , R 011 ') together with the nitrogen atom to which they are attached form an aromatic or non-aromatic ring containing 5 to 7 ring members, which optionally contains, in addition to said nitrogen atom, 1 to 3 heteroatoms selected from O, S and N, wherein said N atom is linear or branched (C 1 ~C 6 ) alkyl groups, wherein the linear or branched (C 1 ~C 6 ) one or more of the carbon atoms of the alkyl group are optionally deuterated; R 012 is -Cy 05 , -Cy 05 - (C 0 ~C 6 ) alkyl-O-(C 0 ~C 6 ) Alkyl-Cy 06 , -Cy 05 - (C 0 ~C 6 ) Alkyl-Cy 06 , -Cy 05 - (C 0 ~C 6 ) alkyl-NR 011 - (C 0 ~C 6 ) Alkyl-Cy 06 , -Cy 05 -Cy 06 -O-(C 0 ~C 6 ) Alkyl-Cy 07 , -Cy 05 - (C 0 ~C 6 ) alkyl-O-(C 0 ~C 6 ) Alkyl-Cy 09 , -Cy 05 - (C 0 ~C 6 ) Alkyl-Cy 09 , -NH-C(O)-NH-R 011 , -Cy 05 - (C 0 ~C 6 ) alkyl-NR 011 - (C 0 ~C 6 ) Alkyl-Cy 09 , —C(O)—NR 011 R 011 ', -NR 011 R 011 ', -OR 011 , -NR 011 -C(O)-R 011 ', -O-(C 1 ~C 6 ) alkyl-OR 011 , -SO 2 -R 011 , —C(O)—OR 011 and R 013 , R 013 ', R 014 and R 014 ' are each independently a hydrogen atom or an optionally substituted linear or branched (C 1 ~C 6 ) alkyl group, R 0a is a hydrogen atom or a linear or branched (C 1 ~C 6 ) alkyl group, R 0b is -O-C(O)-O-R 0c group, -OC(O)-NR 0c R 0c ' group or -O-P(O)(OR 0c ) 2 It is based on R 0c and R 0c ' are each independently a hydrogen atom, a linear or branched (C 1 ~C 8 ) an alkyl group, a cycloalkyl group, (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) alkyl group or (C 1 ~C 6 ) alkoxycarbonyl (C 1 ~C 6 ) alkyl group, Or against (R 0c , R 0c ') together with the nitrogen atom to which they are attached form a non-aromatic ring consisting of 5 to 7 ring members, which may contain, in addition to said nitrogen atom, 1 to 3 heteroatoms selected from oxygen and nitrogen, wherein said nitrogen is linear or branched (C 1 ~C 6 ) optionally substituted with an alkyl group; Cy 01 , Cy 02 , Cy 03 , Cy 04 , Cy 05 , Cy 06 , Cy 07 , Cy 08 and Cy 010 are, independently of each other, a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, each of which is optionally substituted; Cy 09 teeth [66] and Or Cy 09 is -OP(O)(OR 020 ) 2 ;-OP(O)(O - M + ) 2 ;-(CH 2 ) p0 -O-(CHR 018 -CHR 019 -O) q0 -R 020 ; Hydroxy; Hydroxy(C 1 ~C 6 ) alkyl; -(CH 2 ) r0 -U 0 - (CH 2 ) s0 -heterocycloalkyl; and -U 0 - (CH 2 ) q0 -NR 021 R 021 ', R 015 is a hydrogen atom; -(CH 2 ) p0 -O-(CHR 018 -CHR 019 -O) q0 -R 020 Group; Linear or branched (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) alkyl group; 0 - (CH 2 ) q0 -NR 021 R 021 ' group; or -(CH 2 ) r0 -U 0 - (CH 2 ) s0 -heterocycloalkyl group, R 016 is a hydrogen atom; a hydroxy group; a hydroxy (C 1 ~C 6 ) alkyl group; 2 ) r0 -U 0 - (CH 2 ) s0 -heterocycloalkyl group; (CH 2 ) r0 -U 0 -V 0 -O-P(O)(OR 020 ) 2 Group; -O-P(O)(O - M + ) 2 Group: —O—S(O) 2 OR 020 Group;-S(O) 2 OR 020 Group;-(CH 2 ) p0 -O-(CHR 018 -CHR 019 -O) q0 -R 020 Group;-(CH 2 ) p0 -O-C(O)-NR 022 R 023 group; or -U 0 - (CH 2 ) q0 -NR 021 R 021 ' is a base, R 017 is a hydrogen atom; -(CH 2 ) p0 -O-(CHR 018 -CHR 019 -O) q0 -R 020 Group;-CH 2 -P(O)(OR 020 ) 2 group, -OP(O)(OR 020 ) 2 Group; -O-P(O)(O - M + ) 2 Group; Hydroxy group; Hydroxy (C 1 ~C 6 ) alkyl group; 2 ) r0 -U 0 - (CH 2 ) s0 -heterocycloalkyl group; -U 0 - (CH 2 ) q0 -NR 021 R 021 ' group; or an aldonic acid, M + is a pharma- ceutically acceptable monovalent cation; U 0 is a bond or an oxygen atom, V 0 is -(CH 2 ) s0 - group or -C(O)- group, R 018 is a hydrogen atom or (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) alkyl group, R 019 is a hydrogen atom or a hydroxyl (C 1 ~C 6 ) alkyl group, R 020 is a hydrogen atom or a linear or branched (C 1 ~C 6 ) alkyl group, R 021 and R 021 ' are each independently a hydrogen atom, a linear or branched (C 1 ~C 6 ) alkyl group, or hydroxy (C 1 ~C 6 ) alkyl group, Or against (R 021 , R 021 ') together with the nitrogen atom to which they are attached form an aromatic or non-aromatic ring containing 5 to 7 ring members, which optionally contains, in addition to said nitrogen atom, 1 to 3 heteroatoms selected from O, S and N, wherein said resulting ring can be optionally substituted with hydrogen atoms or linear or branched (C 1 ~C 6 ) optionally substituted with an alkyl group; R 022 (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) alkyl group, —(CH 2 ) p0 -NR 024 R 024 ' group or -(CH 2 ) p0 -O-(CHR 018 -CHR 019 -O) q0 -R 20 It is based on R 023 is a hydrogen atom or (C 1 ~C 6 ) Alkoxy (C 1 ~C 6 ) alkyl group, Or against (R 022 , R 023 ) together with the nitrogen atom to which they are attached form an aromatic or non-aromatic ring containing 5 to 18 ring members, which optionally contains, in addition to said nitrogen atom, 1 to 5 heteroatoms selected from O, S and N, wherein said resulting ring can be optionally substituted with hydrogen atoms, linear or branched (C 1 ~C 6) optionally substituted with an alkyl or heterocycloalkyl group; R 024 and R 024 ' are each independently a hydrogen atom or a linear or branched (C 1 ~C 6 ) alkyl group, Or against (R 024 , R 024 ') together with the nitrogen atom to which they are attached form an aromatic or non-aromatic ring consisting of 5 to 7 ring members, which may contain, in addition to said nitrogen atom, 1 to 3 heteroatoms selected from O, S and N, wherein said resulting ring is not limited to hydrogen atoms or linear or branched (C 1 ~C 6 ) optionally substituted with an alkyl group; R 025 is a hydrogen atom, a hydroxyl group or a hydroxyl (C 1 ~C 6 ) alkyl group, R 026 is a hydrogen atom, a halogen atom, a linear or branched (C 1 ~C 6 ) an alkyl group or a cyano group; R 027 is a hydrogen atom or a linear or branched (C 1 ~C 6 ) alkyl group, R 028 is -O-P(O)(O - ) (O - ) group, —O—P(O)(O - ) (OR 030 ) group, -OP(O)(OR 030 ) (OR 030 ') group, -(CH 2 ) p0 -O-SO 2 -O - group, -(CH 2 ) p0 -SO 2 -O - group, -(CH 2 ) p0 -O-SO 2 -OR 030group, -Cy 010 , -(CH 2 ) p0 -SO 2 -OR 030 group, -O-C(O)-R 029 group, -OC(O)-OR 029 Group or -O-C(O)-NR 029 R 029 ' is a base, R 029 and R 029 ' are each independently a hydrogen atom, a linear or branched (C 1 ~C 6 ) alkyl group or linear or branched amino (C 1 ~C 6 ) alkyl group, R 030 and R 030 ' are each independently a hydrogen atom, a linear or branched (C 1 ~C 6 ) alkyl group or aryl (C 1 ~C 6 ) alkyl group, R 031 teeth [67] wherein the ammonium is optionally present in zwitterionic form or has a monovalent anionic counterion; n 0 is an integer equal to 0 or 1, p 0 is an integer equal to 0, 1, 2, or 3, q 0 is an integer equal to 1, 2, 3, or 4, r 0 and s 0 are integers independently equal to 0 or 1, Here, at most, the R 03 group, R 09 Group or R 012 one of the groups, when present, is covalently attached to said linker; where the valency of the atom is not exceeded by one or more of the substituents attached to it. or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing; (ii) D is a compound of formula (II): [68] (In the formula, Z 0 is a nitrogen atom or a C—R 04 group, R 01 is a halogen atom, a linear or branched (C 1 -C 6 ) alkyl group, a linear or branched (C 2 -C 6 ) alkenyl group, a linear or branched (C 2 -C 6 ) alkynyl group, a linear or branched (C 1 -C 6 ) haloalkyl group, a hydroxy group, a linear or branched (C 1 -C 6 ) alkoxy group, a -S-(C 1 -C 6 ) alkyl group, a cyano group, -Cy 08 , -NR 011 R 011 '; R 02 , R 03 and R 04 each independently represent a hydrogen atom, a halogen atom, a linear or branched (C 1 -C 6 ) alkyl group, a linear or branched (C 2 -C 6 ) alkenyl group, a linear or branched (C 2 -C 6 ) alkynyl group, a linear or branched (C 1 -C 6 ) haloalkyl, a hydroxy group, a linear or branched (C 1 -C 6 ) alkoxy group, -S-(C 1 -C 6 ) alkyl group, a cyano group, a nitro group, -(C 0 -C 6 ) alkyl-NR 011 R 011 ', -O-Cy 01 , -(C 0 -C 6 ) alkyl-Cy 01 , -(C 2 -C 6 ) alkenyl-Cy 01 , -(C 2 -C 6 )alkynyl-Cy 01 , -O-(C 1 -C 6 )alkyl-NR 011 R 011 ', -O-(C 1 -C 6 )alkyl-R 031 , -C(O)-OR 011 , -O-C(O)-R 011 , -C(O)-NR 011 R 011 ', -NR 011 -C(O)-R 011 ', -NR 011 -C(O)-OR 011 ', -(C 1 -C 6 )alkyl-NR 011 -C(O)-R 011 ', -SO 2 -NR 011 R 011 ', or -SO 2 -(C 1 -C 6 )alkyl; or the pair (R 02 , R 03 ) or (R 03 , R 04 ) together with the carbon atom to which they are attached form an aromatic or non-aromatic ring containing 5 to 7 ring members, optionally containing 1 to 3 heteroatoms selected from O, S and N, said ring being optionally substituted with a group selected from linear or branched (C 1 -C 6 ) alkyl, -NR 013 R 013 ', -(C 0 -C 6 ) alkyl-Cy 01 and oxo; R 06 and R 07 are each independently a hydrogen atom, a halogen atom, a linear or branched (C 1 -C 6 ) alkyl group, a linear or branched (C 2 -C 6 ) alkenyl group, a linear or branched (C 2 -C 6 ) alkynyl group, a linear or branched (C 1 -C 6 ) haloalkyl, a hydroxy group, a linear or branched (C 1 -C 6 ) alkoxy group, -S-(C 1 -C 6 ) alkyl group, a cyano group, a nitro group, -(C 0 -C 6 ) alkyl-NR 011 R 011 ', -O-Cy01, -(C0-C6)alkyl-Cy01, -(C2-C6)alkenyl-Cy01, -(C2-C6)alkynyl-Cy01, -O-(C 1 -C 6 )alkyl-R 012 , -C(O)-OR 011 , -O-C(O)-R 011 , -C(O)-NR 011 R 011 ', -NR 011 -C(O)-R 011 ', -NR 011 -C(O)-OR 011 ', -(C 1 -C 6 )alkyl-NR 011 -C(O)-R 011 ', -SO 2 -NR 011 R 011 ', or -SO2-(C1-C6)alkyl; or the pair (R 06 , R 07 ), when fused with two adjacent carbon atoms, together with the carbon atom to which they are attached, form an aromatic or non-aromatic ring containing from 5 to 7 ring members, optionally containing from 1 to 3 heteroatoms selected from O, S and N, said resulting ring being optionally substituted with groups selected from linear or branched (C 1 -C 6 )alkyl groups, -NR 013 R 013 ', -(C 0 -C 6 )alkyl-Cy 01 and oxo; R 08 is a hydrogen atom, a linear or branched (C 1 -C 8 ) alkyl group, an aryl group, a heteroaryl group, an aryl-(C 1 -C 6 ) alkyl group or a heteroaryl(C 1 -C 6 ) alkyl group; R 09 is a linear or branched (C 1 -C 6 ) alkyl group, a linear or branched (C 2 -C 6 ) alkenyl group, a linear or branched (C 2 -C 6 ) alkynyl group, -Cy 02 , -(C 1 -C 6 ) alkyl-Cy 02 , -(C 2 -C 6 ) alkenyl-Cy 02 , -(C 2 -C 6 ) alkynyl-Cy 02 , -Cy 02 -Cy 03 , -(C 2 -C 6 ) alkynyl-O-Cy 02 , -Cy 02 -(C 0 -C 6 ) alkyl-O-(C 0 -C 6 ) alkyl-Cy 03 , a halogen atom, a cyano group, -C(O)-R 014 , -C(O)-NR 014 R 014 ', R 011 and R 011 ′ are each independently a hydrogen atom, an optionally substituted linear or branched (C 1 -C 6 ) alkyl group, or —(C 0 -C 6 ) alkyl-Cy 01 ; or the pair (R 011 , R 011 ') together with the nitrogen atom to which they are attached form an aromatic or non-aromatic ring containing 5 to 7 ring members, which optionally contains, in addition to said nitrogen atom, 1 to 3 heteroatoms selected from O, S and N, wherein said N atom is optionally substituted with a linear or branched (C 1 -C 6 ) alkyl group, wherein one or more of the carbon atoms of said linear or branched (C 1 -C 6 ) alkyl group are optionally deuterated; R 012 is -Cy 05 , -Cy 05 -(C 0 -C 6 )alkyl-Cy 06 , -Cy 05 -(C 0 -C 6 )alkyl-O-(C 0 -C 6 )alkyl-Cy 06 , -Cy 05 -(C 0 -C 6 )alkyl-NR 011 -(C 0 -C 6 )alkyl-Cy 06 , -Cy 05 -Cy 06 -O-(C 0 -C 6 )alkyl-Cy 07 , -Cy 05 -(C 0 -C 6 )alkyl-Cy 09 , -NH-C(O)-NH-R 011 , -C(O)-NR 011 R 011 ', -NR 011 R 011 ', -OR 011 , -NR 011 -C(O)-R 011 ', -O-(C 1 -C 6 )alkyl-OR 011 , -SO 2 -R 011 , or -C(O)-OR 011 ; R 013 , R 013 ', R 014 and R 014 ' are each independently a hydrogen atom or an optionally substituted linear or branched (C 1 -C 6 ) alkyl group; Cy 01 , Cy 02 , Cy 03 , Cy 05 , Cy 06 , Cy 07 and Cy 08 are each independently a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, each of which is optionally substituted; Cy09 is [69] and wherein R 015 , R 016 and R 017 are as defined for formula (I); R031 is [C70] where R 027 and R 028 are as defined for formula (I); wherein at most one of the R 03 , R 09 or R 012 groups, if present, is covalently attached to the linker. or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing; (iii) D is of formula (III): [C71] (In the formula, R 01 is a linear or branched (C 1 -C 6 ) alkyl group; R 03 is —O—(C 1 -C 6 )alkyl-NR 011 R 011 ′, or [C72] and wherein R 011 and R 011 ′ are each independently a hydrogen atom, an optionally substituted linear or branched (C 1 -C 6 ) alkyl group, or —(C 0 -C 6 ) alkyl-Cy 01 ; or the pair (R 011 , R 011 ') together with the nitrogen atom to which they are attached form an aromatic or non-aromatic ring containing 5 to 7 ring members, which optionally contains, in addition to said nitrogen atom, 1 to 3 heteroatoms selected from O, S and N, wherein said N atom may be substituted by 1 or 2 groups selected from hydrogen atoms or linear or branched (C 1 -C 6 ) alkyl groups, In the above, R 027 is a hydrogen atom, R 028 is a —(CH 2 ) p0 —O—SO 2 —O − group or a —(CH 2 ) p0 —SO 2 —OR 030 group; R 09 is a linear or branched (C 2 -C 6 ) alkynyl group or -Cy 02 ; R 012 is -Cy 05 , -Cy 05 -(C 0 -C 6 )alkyl-Cy 06 or -Cy 05 -(C 0 -C 6 )alkyl-Cy 09 ; Cy 01 , Cy 02 , Cy 05 and Cy 06 are each independently a cycloalkyl group, a heterocycloalkyl group, an aryl group or a heteroaryl group, each of which is optionally substituted; Cy09 is [C73] and R 015 , R 016 and R 017 are as defined for formula (I); wherein at most one of the R 03 , R 09 or R 012 groups, if present, is covalently attached to the linker. or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing. (i) D comprises a compound of formula (I), During the ceremony, Cy 01 , Cy 02 , Cy 03 , Cy 04 , Cy 05 , Cy 06 , Cy 07 , Cy 08 and Cy 010 are each independently a cycloalkyl group, a heterocycloalkyl group, an aryl group, or a heteroaryl group, each of which is halo; 1 ~C 6 ) alkoxy; -(C 1 ~C 6 ) haloalkyl; -(C 1 ~C 6 ) haloalkoxy; -(CH 2 ) p0 -O-SO 2 -OR 030;-(CH 2 ) p0 -SO 2 -OR 030 ;-OP(O)(OR 020 ) 2 ;-OP(O)(O - M + ) 2 ;-CH 2 -P(O)(OR 020 ) 2 ; - (CH 2 ) p0 -O-(CHR 018 -CHR 019 -O) q0 -R 020 ; Hydroxy; Hydroxy(C 1 ~C 6 ) alkyl; -(CH 2 ) r0 -U 0 - (CH 2 ) s0 -heterocycloalkyl; or -U 0 - (CH 2 ) q0 -NR 021 R 021 Optionally substituted with one or more groups selected from: (iii) D comprises a compound of formula (III): During the ceremony, (1) R 01 is methyl or ethyl; (2) R 03 is -O-CH 2 -CH 2 -NR 011 R 011 ', where R 011 and R 011 ' together with the nitrogen atom carrying them form a piperazinyl group which may be substituted with a hydrogen atom or a linear or branched (C 1 -C 6 ) alkyl group; (3) R 03 is a compound represented by the formula: [C74] (wherein R 027 is a hydrogen atom and R 028 is a —(CH 2 ) p0 —SO 2 —OR 030 group). Contains; (4) R 03 is a compound represented by the formula: [C75] (In the formula, [C76] is the bond to the linker) Contains; (5) R 09 is Cy 02 ; (6) Cy 02 is an optionally substituted aryl group; (7) Cy 05 comprises a heteroaryl group selected from a pyrazolyl group and a pyrimidinyl group; or (8) Cy 05 is a pyrimidinyl group; Optionally, The antibody-drug conjugate of any one of claims 1 to 10, wherein L is attached to D by a covalent bond from L to R 03 of formula (I), (II) or (III), or L is attached to D by a covalent bond from L to R 09 of formula (I), (II) or (III).

12. (1) D is, [C77] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (2) D: [C78] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (3) D is [C79] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (4) D is [C80] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (5) D is [chemical 81] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (6) D is [chemical 82] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (7) D is [chemical 83] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (8) D is [chemical 84] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (9) D is [C85] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (10) D is [chemical 86] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (11) D is [chemical 87] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (12) D is [C88] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, or (13) D is [C89] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (14) D is [C90] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (15) D is [C91] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, (16) D is [C92] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing, or (17) D is [C93] or enantiomers, diastereoisomers, atropisomers, deuterated derivatives, and / or pharma- ceutically acceptable salts of any of the foregoing; or The antibody-drug conjugate according to any one of claims 1 to 11, wherein (18)-(L-D) is formed from a compound selected from the following compounds or an enantiomer, diastereoisomer, atropisomer, deuterated derivative, and / or a pharma- ceutically acceptable salt thereof: [C94-1] , [ka] , 【change】 , 【change】 , 【Chemistry 94-2】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-3】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-4】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-5】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-6】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-7】 , 【change】 , 【change】 , 【Chemistry 94-8】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-9】 , 【change】 , 【change】 , 【Chemistry 94-10】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-11】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-12】 , 【change】 , 【change】 , 【change】 , 【Chemistry 94-13】 , 【change】 , 【change】 , 【Chemistry 94-14】 , 【change】 , 【change】 , 【Chemistry 94-15】 , 【change】 , 【Chemistry 94-16】 , 【change】 , 【Chemistry 94-17】 , 【change】 , 【Chemistry 94-18】 , 【change】 , 【Chemistry 94-19】 , 【change】 , 【Chemistry 94-20】 , 【change】 , 【Chemistry 94-21】 , 【change】 , 【change】 , 【Chemistry 94-22】 , 【change】 , 【change】 , 【Chemistry 94-23】 , 【change】 , 【change】 , 【Chemistry 94-24】 , 【change】 , 【change】 , 【Chemistry 94-25】 , 【change】 , 【Chemistry 94-26】 , 【change】 , 【Chemistry 94-27】 , 【change】 , 【Chemistry 94-28】 , 【change】 , 【Chemistry 94-29】 , 【change】 , 【Chemistry 94-30】 , 【change】 , 【change】 , 【Chemistry 94-31】 , 【change】 , 【change】 , 【Chemistry 94-32】 , 【change】 , 【Chemistry 94-33】 , 【change】 , 【change】 , 【Chemistry 94-34】 , 【change】 , 【Chemistry 94-35】 , 【change】 , 【Chemistry 94-35】 , 【change】 , 【Chemistry 94-36】 , 【change】 , 【change】 , [C94-37] , [ka] , [C94-38] , [ka] , [ka] , [C94-39] , [ka] , [94-40] , [ka] , [C94-41] , [ka] , [C94-42] , [ka] , [C94-43] , [ka] , [C94-44] , [ka] , or [C94-45] , 13. The method of claim 1, wherein the anti-CD48 antibody or antigen-binding fragment thereof is (i) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 10, and a light chain variable region comprising the amino acid sequence of SEQ ID NO: 23; or (ii) a heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 36, and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

49. Contains; (2) The anti-CD48 antibody is (a) a heavy chain amino acid sequence of SEQ ID NO: 12 and a light chain amino acid sequence of SEQ ID NO: 25; (b) a heavy chain amino acid sequence of SEQ ID NO: 14 and a light chain amino acid sequence of SEQ ID NO: 25; (c) a heavy chain amino acid sequence of SEQ ID NO: 38 and a light chain amino acid sequence of SEQ ID NO: 51; or (d) a heavy chain amino acid sequence of SEQ ID NO: 40 and a light chain amino acid sequence of SEQ ID NO:

51. The antibody-drug conjugate of any one of claims 1 to 12, comprising:

14. 14. A composition comprising multiple copies of the antibody-drug conjugate of any one of claims 1 to 13, wherein the average p of the antibody-drug conjugate in the composition is from about 2 to about 16, from about 2 to about 8, from about 2 to about 4.

15. A pharmaceutical composition comprising the antibody-drug conjugate of any one of claims 1 to 13 or the composition of claim 14, and a pharma- ceutically acceptable carrier.

16. A pharmaceutical composition for use in a method of treating a subject having or suspected of having cancer, said pharmaceutical composition comprising an antibody-drug conjugate according to any one of claims 1 to 13, a composition according to claim 14, or a pharmaceutical composition according to claim 15, Optionally, (i) the cancer expresses CD48; (ii) the cancer is a tumor or blood cancer, preferably the cancer is breast cancer, multiple myeloma, plasma cell myeloma, leukemia, lymphoma, gastric cancer, acute myeloid leukemia, bladder cancer, brain cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, B-cell lymphoma, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, prostate cancer, small cell lung cancer or splenic cancer; Pharmaceutical compositions.

17. A pharmaceutical composition for use in a method for reducing or inhibiting tumor growth in a subject, the pharmaceutical composition comprising an antibody-drug conjugate according to any one of claims 1 to 13, a composition according to claim 14, or a pharmaceutical composition according to claim 15, Optionally, (a) the tumor expresses CD48; (b) The pharmaceutical composition, wherein the tumor is breast cancer, gastric cancer, bladder cancer, brain cancer, cervical cancer, colorectal cancer, esophageal cancer, hepatocellular carcinoma, melanoma, oral cancer, ovarian cancer, non-small cell lung cancer, prostate cancer, small cell lung cancer or splenic cancer.

18. The pharmaceutical composition of claim 16 or 17, wherein administration of the antibody-drug conjugate, composition or pharmaceutical composition reduces or inhibits the growth of the tumor by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95% or at least about 99%.

19. A pharmaceutical composition for use in a method for reducing or slowing the expansion of a cancer cell population in a subject, comprising an antibody-drug conjugate according to any one of claims 1 to 13, a composition according to claim 14, or a pharmaceutical composition according to claim 15. Optionally, (I) the cancer cell population expresses CD48; (II) the cancer cell population is derived from a tumor or a hematological cancer; and / or (III) The pharmaceutical composition, wherein the cancer cell population is derived from breast cancer, multiple myeloma, plasma cell myeloma, leukemia, lymphoma, gastric cancer, acute myeloid leukemia, bladder cancer, brain cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, B-cell lymphoma, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, prostate cancer, small cell lung cancer, or splenic cancer.

20. 20. The pharmaceutical composition of claim 19, wherein administration of the antibody-drug conjugate, composition or pharmaceutical composition reduces the cancer cell population or slows the expansion of the cancer cell population by at least about 10%, at least about 20%, at least about 30%, at least about 40%, at least about 50%, at least about 60%, at least about 70%, at least about 80%, at least about 90%, at least about 95% or at least about 99%.

21. A pharmaceutical composition for use in a method for determining whether a subject having or suspected of having cancer will respond to treatment with an antibody-drug conjugate according to any one of claims 1 to 13, a composition according to claim 14, or a pharmaceutical composition according to claim 15, comprising: the method comprising: providing a biological sample from the subject; contacting the sample with the antibody-drug conjugate; and detecting binding of the antibody-drug conjugate to cancer cells in the sample; Optionally, (i) the cancer cells in the sample express CD48; (ii) the cancer expresses CD48; (iii) the cancer is a tumor or a blood cancer; (iv) the cancer is breast cancer, multiple myeloma, plasma cell myeloma, leukemia, lymphoma, gastric cancer, acute myeloid leukemia, bladder cancer, brain cancer, bone marrow cancer, cervical cancer, chronic lymphocytic leukemia, colorectal cancer, esophageal cancer, hepatocellular carcinoma, lymphoblastic leukemia, follicular lymphoma, lymphoid malignancies of T-cell or B-cell origin, B-cell lymphoma, melanoma, myeloid leukemia, myeloma, oral cancer, ovarian cancer, non-small cell lung cancer, chronic lymphocytic leukemia, prostate cancer, small cell lung cancer or splenic cancer; and / or (v) The pharmaceutical composition, wherein the sample is a tissue biopsy sample, a blood sample or a bone marrow sample.

22. The method further comprising administering to the subject in need thereof at least one additional therapeutic agent, preferably said one additional therapeutic agent is a Bcl-2 inhibitor, more preferably said one additional therapeutic agent is: (i) venetoclax, (ii) [C95] or (iii) [C96] 21. The pharmaceutical composition according to any one of claims 16 to 20, wherein

23. 14. A method of making an antibody-drug conjugate according to any one of claims 1 to 13, comprising reacting an anti-CD48 antibody or antigen-binding fragment of claim 1 with a cleavable linker linked to an MCL1 inhibitor under conditions that allow conjugation.

24. Formula (1): Ab-(L-D) p (1) (In the formula, the Ab is an anti-CD48 antibody or antigen-binding fragment thereof, optionally wherein said Ab is an Fc-silenced antibody; p is an integer from 1 to 16; L is a linker, D is an MCL1 inhibitor compound. Antibody-drug conjugates of.

25. 25. A pharmaceutical composition for use in a method of treating a disease or disorder, said pharmaceutical composition comprising the antibody-drug conjugate of claim 24 in combination with a Bcl-2 inhibitor, wherein said disease or disorder is mediated by CD48.